SHORTList
Loyal logo
Biotech/Pharma

Loyal

Extending healthy lifespan of dogs

CORE INFO

$216.81M
Total Funding
Series C
Round
2019
Founded
196
Team Size
San Francisco, CA
Headquarters
loyal.com/Website

Loyal is a clinical-stage biotechnology company focused on developing FDA-approved drugs to extend the healthy lifespan of dogs. The company is dedicated to creating therapeutics that target the underlying mechanisms of aging, aiming to delay the onset and reduce the severity of age-related diseases in canines. Their lead product, LOY-002, is a daily flavored tablet designed for senior dogs aged 10 and older, targeting metabolic dysfunction to improve healthspan and lifespan. Additionally, Loyal is working on LOY-001 and LOY-003, which aim to extend the healthy lifespan of large-breed dogs by addressing overexpression of IGF-1 and growth hormone post-maturity.

Founded in 2019 and headquartered in San Francisco, California, Loyal has made significant strides in veterinary medicine. The company has raised a total of $216.81 million over nine funding rounds, with the latest being a $100 million Series C round in February 2026. Loyal's mission is to help dogs live longer, healthier lives by focusing on preventive care and delaying the onset of age-associated diseases. The company is also exploring potential implications for human longevity research in the future.

WHY WE WOULD WORK AT LOYAL

Mission-Driven Impact

Join a pioneering team dedicated to extending the healthy lifespan of dogs, making a tangible difference in pet health and longevity.

Innovative Biotechnology

Engage with cutting-edge research, developing FDA-approved therapeutics targeting aging mechanisms in canines, with future implications for human health.

Rapid Growth Opportunities

Be part of a fast-growing company that has secured $216.81 million in funding, offering ample room for career advancement and professional development.

Collaborative Culture

Work alongside a passionate team of 196 professionals in a supportive environment that values innovation and teamwork.

Industry Recognition

Contribute to a company recognized for its groundbreaking work, including significant strides towards FDA approval for its lead product, LOY-002.

Competitive Compensation

Benefit from attractive compensation packages, backed by strong investor confidence and substantial funding rounds.

MARKET AND TRACTION

GROWTH TACTICS

  • Loyal has successfully raised $216.81 million over nine funding rounds, demonstrating strong investor confidence in their mission.

  • The company is focusing on developing FDA-approved drugs to extend the healthy lifespan of dogs, with LOY-002 being their lead product.

  • Loyal is exploring potential implications for human longevity research, expanding their market reach beyond veterinary medicine.

    • KEY METRICS

    ✦ KEY METRIC
  • Loyal has enrolled 1,300 senior dogs in a pivotal clinical study for LOY-002 across 70 veterinary clinics nationwide.

  • The company has completed two out of three major requirements for conditional FDA approval of LOY-002, including the safety package (TAS).

  • Loyal's team has grown to approximately 196 employees as of March 2026, reflecting their expansion and development efforts.

    • COMPETITIVE ADVANTAGE

  • Loyal is pioneering the development of the first FDA-approved longevity drug for dogs, positioning them as leaders in veterinary biotechnology.

  • Their focus on addressing the underlying mechanisms of aging provides a unique approach to extending the healthy lifespan of dogs.

  • Loyal's research and development efforts are supported by significant funding, allowing them to advance their clinical-stage products effectively.

    • MARKET POSITION

  • Loyal operates within the biotechnology and pharmaceutical industries, specifically targeting veterinary medicine and pet health.

  • The company is headquartered in San Francisco, California, a hub for innovation and biotechnology.

  • Loyal's mission to delay the onset and reduce the impact of age-associated diseases in dogs aligns with growing consumer interest in pet health and longevity.

    • COMPANY CULTURE

    Values

  • Commitment to canine health and longevity

  • Emphasis on preventive care and innovation

  • Dedication to scientific rigor and research excellence

  • Transparency and integrity in all operations

    • Operating Principles

  • Prioritize safety and efficacy in drug development

  • Foster collaboration across multidisciplinary teams

  • Engage with veterinary professionals and pet owners

  • Maintain a focus on long-term impact and sustainability

    • Benefits

  • Opportunity to contribute to groundbreaking veterinary medicine

  • Work with a passionate and mission-driven team

  • Access to professional development and growth opportunities

  • Flexible work environment supporting work-life balance

    • Team Cadence

  • Regular cross-functional meetings to align on goals

  • Open communication channels for feedback and ideas

  • Collaborative project management approach

  • Emphasis on agile methodologies to adapt to new challenges

    • Learning & Growth

  • Encouragement of continuous learning and skill development

  • Support for attending industry conferences and workshops

  • Access to a network of experts and mentors in biotechnology

  • Opportunities for career advancement within the company

    • PRODUCT AND TECH

    LOY-002 Therapeutic Tablet

    A daily flavored tablet designed for senior dogs aged 10 and older, targeting metabolic dysfunction to improve healthspan and lifespan. This product is pivotal in delaying the onset of age-related diseases in canines.

    LOY-001 and LOY-003

    These therapeutics aim to extend the healthy lifespan of large-breed dogs by addressing overexpression of IGF-1 and growth hormone post-maturity. They are crucial for enhancing longevity in specific dog breeds.

    Biotechnology Innovations

    Loyal specializes in developing FDA-approved drugs that target the underlying mechanisms of aging in dogs. This approach is essential for creating preventive care solutions that delay age-associated diseases.

    Veterinary Clinical Trials

    Loyal conducts extensive clinical studies, enrolling senior dogs across numerous veterinary clinics to validate the efficacy of their therapeutics. These trials are critical for achieving FDA approval and ensuring product safety.

    Longevity Research Implications

    While focusing on canine health, Loyal explores potential applications of their research in human longevity. This cross-species research could revolutionize aging treatments beyond veterinary medicine.